Aqneursa levacetylleucine?

What is Aqneursa?
Aqneursa is an over‑the‑counter product marketed in several countries as a supplement aimed at reducing fatigue and improving mental focus. The label lists levacetyl‑leucine as the active ingredient.

What is levacetyl‑leucine and how does it work?
Levacetyl‑leucine is a chemically modified form of the amino acid leucine. It is absorbed quickly and is thought to cross the blood‑brain barrier, where it can be converted to acetyl‑L‑glutamine, a compound that may support energy metabolism in neurons. Clinical studies suggest modest improvements in subjective fatigue scores, but larger trials are limited.

Is levacetyl‑leucine the only ingredient in Aqneursa?
The core formulation contains levacetyl‑leucine. Some versions also include minor excipients such as microcrystalline cellulose or magnesium stearate, but no additional active compounds are listed.

How do I use Aqneursa for fatigue?
Typical dosing ranges from 1–2 g per day, divided into two or three doses. The product recommends taking it with a meal to improve absorption, but individual instructions can vary by formulation. It is not intended as a replacement for medical treatment of underlying conditions that cause fatigue.

Are there any safety concerns or side effects?
Levacetyl‑leucine is generally well tolerated. Mild gastrointestinal upset, headache, or dizziness have been reported in a few cases. Because it is a nutritional supplement, it is not subject to the same regulatory scrutiny as prescription drugs, so batch variability can occur.

Who manufactures Aqneursa?
The brand is produced by a European nutraceutical company that specializes in amino‑acid–based products. The company distributes the supplement mainly in the EU and neighboring markets.

What about patent status and exclusivity for levacetyl‑leucine?
Levacetyl‑leucine itself was first patented in the 1990s. The primary patents on the synthesis method and its use for fatigue relief have largely expired, allowing generic manufacturers to produce similar formulations. Patents on specific formulations, such as the Aqneursa version, may still be in force, but the core compound is no longer under exclusive protection. Detailed patent data can